Qualigen Therapeutics Secures Global Patent Protection for Cancer Drug QN-302 Across 25+ Countries
Key Insights
Qualigen Therapeutics (search) has been granted new patents covering QN-302, a cancer drug candidate targeting pancreatic and gastrointestinal cancers, across more than 25 countries including over 20 European nations, India, China, and Russia.
The patents, titled "Substituted Naphthalene Diimides (search) and Their Use," cover both the drug composition and manufacturing methods, with protection extending into 2040.
Company shares surged 20% following the announcement, with trading volume reaching over 44 million shares compared to the average of 23,000 shares.
Qualigen Therapeutics (search) has significantly strengthened its intellectual property position by securing patent protection for its lead cancer drug candidate QN-302 across more than 25 countries, the company announced on July 16, 2025. The milestone triggered a 20% surge in the company's stock price, with shares jumping from $3.53 to $5.49 at opening.
Comprehensive Global Patent Coverage
The newly granted patents, titled "Substituted Naphthalene Diimides (search) and Their Use," provide protection for both the composition and manufacturing methods of QN-302. The drug was originally developed by Professor Stephen Neidle and his team at University College London and is exclusively licensed to Qualigen Therapeutics (search).
Through validations and processes across Europe, the patents now cover over 20 European countries, representing the majority of the European population. Additionally, Qualigen has secured similar patent coverage in India, China, and Russia, with all protections extending into 2040.
Market Response and Strategic Implications
The patent announcement generated significant investor interest, with trading volume reaching over 44 million shares compared to the typical average of 23,000 shares. This dramatic increase in trading activity reflects the market's recognition of the strategic value of comprehensive intellectual property protection in pharmaceutical development.
"Having the patents granted covering so much of the world's population strengthens our position as a drug development company," stated Kevin Richardson II, CEO of Qualigen. "By assuring such strong coverage will allow us to continue bringing QN-302 to market and treating patients suffering from Pancreatic and Gastrointestinal Cancer (search)."
Therapeutic Focus and Development Pipeline
QN-302 is being developed as a treatment for pancreatic and gastrointestinal cancers, representing a significant therapeutic area with substantial unmet medical needs. The robust intellectual property protection across major global markets positions Qualigen to pursue commercialization strategies in key territories.
The company has indicated that additional patents are in various stages of the approval process, with some already published and others pending. Qualigen plans to provide periodic updates on new patent grants as they are received, suggesting an ongoing expansion of its intellectual property portfolio.